Unichem enters settlement pact with Eli Lilly, ICOS Corp for erectile dysfunction drug
New Delhi: Unichem Laboratories said it has entered into a settlement pact with pharma major Eli Lilly & Company and ICOS Corporation for resolving their patent litigation regarding generic tadalafil used for treating erectile dysfunction.
The patent litigation was in the US District Court for New Jersey, Unichem said.
The company "has entered into a settlement agreement with Eli Lilly & Company and ICOS Corporation to resolve their patent litigation in the US District Court for District of New Jersey regarding Unichem's Abbreviated New Drug Application for generic tadalafil (CialisB)," it said in a BSE filing.
Under the agreement, Unichem expects to launch its generic tadalafil product in the US on or not before March 26, 2019, under certain circumstances, the company said.
It, however, did not provide any details about the 'certain circumstances'.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd